DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4cfd16/diagnostics_for_th) has announced the addition of Decision Resources, Inc.'s new report "Diagnostics for the Developing World: Supporting Global Citizenship" to their offering.
Best outcomes in disease management begin with early diagnosis, which can reduce morbidity, mortality, and negative economic impact. Nowhere are differential and definitive diagnostics more important than in underserved populations for whom poor infrastructure and systemic instability are ever-present barriers to accessibility. Multitudes of opportunities exist in diagnostics development, particularly to address the detection of neglected tropical diseases (NTDs) in developing countries. Companies of all sizes are beginning to avail themselves of resources to develop minimally invasive disease analytics that are both reliable and portable far away from clinics and reference labs. A sound strategy to meeting the needs of the developing world through diagnostics is through the formation of partnerships of people, communities, governments, companies, and nonprofit funding groups. The benefits of diagnostics could accrue immediately, and rewards to companies can be both tangible and lasting.
Scope:
Indications featured: Tuberculosis, malaria, HIV, Chagas disease, schistosomiasis.
Innovative funding models: corporate licensing, promises to purchase, government grants, funding by nonprofit groups, for-profit shared investing.
Companies to watch: Roche Diagnostics; Abbott Laboratories; GlaxoSmithKline (GSK); Siemens Healthcare; Becton, Dickinson and Company (BD); Philips Healthcare; bioMrieux Clinical Diagnostics; MorphoSys.
Companies Mentioned:
- Abbott Laboratories
- Alnylam Pharmaceuticals
- Becton, Dickinson and Company (BD)
- Bill & Melinda Gates Foundation
- BIO Ventures for Global Health (BVGH)
- bioMrieux Clinical Diagnostics
- Caprion Proteomics
- Caring Capital
- Centers for Disease Control and Prevention (CDC)
- Claros Diagnostics
- Commons Capital
- Emory University's Institute for Drug Development
- Endra
- Enlight Biosciences
- Epoch Biosciences (formerly Epoch Pharmaceuticals)
- FDA
- Foundation for Innovative New Diagnostics (FIND)
- GlaxoSmithKline (GSK)
- iThemba Pharmaceuticals
- Juvenile Diabetes Foundation
- MorphoSys
- PATH
- PETNET Solutions
- Philips Healthcare
- PureTech Ventures
- Roche Diagnostics
- Sabin Vaccine Institute
- Siemens Healthcare
- South Africa's Technology Innovation Agency (TIA)
- The Cystic Fibrosis Foundation
- U.S. Microbics (formerly Global Venture Funding)
- United Nations Programme on HIV and AIDS (UNAIDS)
- Wellcome Trust
- William J. Clinton Presidential Foundation
- Zyomyx
For more information visit http://www.researchandmarkets.com/research/4cfd16/diagnostics_for_th